<--- Back to Details
First PageDocument Content
Pharmaceutical sciences / Immunosuppressants / Monoclonal antibodies / Ustekinumab / Infliximab / Golimumab / Clinical trial / Biologic / Medical prescription / Centocor / Pharmacology / Medicine
Date: 2015-04-22 23:39:46
Pharmaceutical sciences
Immunosuppressants
Monoclonal antibodies
Ustekinumab
Infliximab
Golimumab
Clinical trial
Biologic
Medical prescription
Centocor
Pharmacology
Medicine

Add to Reading List

Source URL: www.pbs.gov.au

Download Document from Source Website

File Size: 156,21 KB

Share Document on Facebook

Similar Documents

Commited to Biologic Innovation

DocID: 1tUBq - View Document

Special Authorization Criteria for Biologic Drugs For each disease category specified below, the biologic drugs listed will only be considered for reimbursement if the patient has failed an adequate trial or experienced

DocID: 1tOXv - View Document

ASX ANNOUNCEMENT 10 February 2014 Cynata Partners With Leading Biologic Product Manufacturer Cynata Therapeutics Ltd (ASX:CYP), announced today that it has signed a manufacturing agreement

DocID: 1tf2X - View Document

Stakeholder Meeting on PDUFA VI Reauthorization September 28, 2015, 1:30 PM – 3.05 PM FDA White Oak Campus, Silver Spring, MD Purpose To discuss the current status of the human drug and biologic review programs, review

DocID: 1t2jx - View Document

Council Report AVMA Council on Biologic and Therapeutic Agents’ report on cat and dog vaccines Donald J. Klingborg, DVM; David R. Hustead, DVM; Elizabeth A. Curry-Galvin, DVM; Nigel R. Gumley, DVM, DABVP; Steven C. Hen

DocID: 1s94L - View Document